Single- and multiple-dose randomized studies of blosozumab, a monoclonal antibody against sclerostin, in healthy postmenopausal women.

@article{McColm2014SingleAM,
  title={Single- and multiple-dose randomized studies of blosozumab, a monoclonal antibody against sclerostin, in healthy postmenopausal women.},
  author={Juliet McColm and Leijun Hu and Theresa Womack and Cheng Cai Tang and Alan Y. Chiang},
  journal={Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research},
  year={2014},
  volume={29 4},
  pages={935-43}
}
Two clinical studies were conducted to assess the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of single and multiple doses (intravenous [iv] and subcutaneous [sc]) of blosozumab in postmenopausal women, including prior/current bisphosphonate (BP) users. In these phase 1, randomized, subject- and investigator-blind, placebo-controlled studies, subjects received escalating doses of blosozumab: single iv doses up to 750 mg, single sc doses of 150 mg, multiple iv doses up… CONTINUE READING
Recent Discussions
This paper has been referenced on Twitter 9 times over the past 90 days. VIEW TWEETS
52 Extracted Citations
12 Extracted References
Similar Papers

Citing Papers

Publications influenced by this paper.
Showing 1-10 of 52 extracted citations

Referenced Papers

Publications referenced by this paper.
Showing 1-10 of 12 references

Blosozumab, a humanizedmonoclonal antibody, and a chimeric rodent monoclonal antibody against sclerostin robustly increase bone formation activity in intactmonkeys and ovariectomized rats

  • YL Ma, T Page, ZengQQ
  • J Bone Miner Res. 2012;(Suppl 1):Available at…
  • 2012

Similar Papers

Loading similar papers…